Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy

A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged administration of these inhibitors indicate the need for...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Bijay, Yang, Shicheng, Krishna, Apurva, Sridhar, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719718/
https://www.ncbi.nlm.nih.gov/pubmed/33330383
http://dx.doi.org/10.3389/fchem.2020.594619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719718/
https://www.ncbi.nlm.nih.gov/pubmed/33330383
http://dx.doi.org/10.3389/fchem.2020.594619

Ejemplares similares